Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasia

Peer Review reports

Original Submission
23 Jan 2017	Submitted	Original manuscript
5 May 2017	Reviewed	Reviewer Report - Nyirády Péter
6 Jun 2017	Reviewed	Reviewer Report - Anastasios Athanasopoulos
6 Jul 2017	Author responded	Author comments - Antoni Sicras-Mainar
Resubmission - Version 2
6 Jul 2017	Submitted	Manuscript version 2
7 Jul 2017	Reviewed	Reviewer Report - Nyirády Péter
13 Jul 2017	Reviewed	Reviewer Report - Anastasios Athanasopoulos
31 Aug 2017	Author responded	Author comments - Antoni Sicras-Mainar
Resubmission - Version 3
31 Aug 2017	Submitted	Manuscript version 3
Publishing
4 Sep 2017	Editorially accepted
12 Sep 2017	Article published	10.1186/s12894-017-0275-6

Back to article page